Advertisement
Singapore markets closed
  • Straits Times Index

    3,290.70
    +24.75 (+0.76%)
     
  • Nikkei

    38,229.11
    +155.13 (+0.41%)
     
  • Hang Seng

    18,963.68
    +425.87 (+2.30%)
     
  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     
  • Bitcoin USD

    60,306.18
    -1,812.55 (-2.92%)
     
  • CMC Crypto 200

    1,251.87
    -106.14 (-7.82%)
     
  • S&P 500

    5,220.33
    +6.25 (+0.12%)
     
  • Dow

    39,474.53
    +86.77 (+0.22%)
     
  • Nasdaq

    16,337.62
    -8.64 (-0.05%)
     
  • Gold

    2,376.40
    +36.10 (+1.54%)
     
  • Crude Oil

    78.41
    -0.85 (-1.07%)
     
  • 10-Yr Bond

    4.5000
    +0.0510 (+1.15%)
     
  • FTSE Bursa Malaysia

    1,600.67
    -0.55 (-0.03%)
     
  • Jakarta Composite Index

    7,088.79
    -34.81 (-0.49%)
     
  • PSE Index

    6,511.93
    -30.53 (-0.47%)
     

Which Is the Better Buy: Vertex or Invitae?

Which Is the Better Buy: Vertex or Invitae?

Vertex Pharmaceuticals (NASDAQ: VRTX) and Invitae (NYSE: NVTA) have gone in different directions this year when it comes to share price, with Vertex's stock up more than 43% so far and Invitae's shares plunging over 84%. Looking at these two biotech stocks from a long-term perspective, is Invitae now the better buy? Or is Vertex's strong run this year likely to extend into 2023?